NASDAQ:JANX Janux Therapeutics (JANX) Stock Price, News & Analysis → The AI Defense Stock Set to Soar (From Behind the Markets) (Ad) Free JANX Stock Alerts $37.92 -0.92 (-2.37%) (As of 03/27/2024 ET) Add Compare Share Share Today's Range$37.50▼$39.6850-Day Range$7.93▼$49.7552-Week Range$5.65▼$58.69Volume397,386 shsAverage Volume1.08 million shsMarket Capitalization$1.96 billionP/E RatioN/ADividend YieldN/APrice Target$59.60 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Janux Therapeutics alerts: Email Address Janux Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside57.2% Upside$59.60 Price TargetShort InterestBearish9.60% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.42Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.40) to ($1.64) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.05 out of 5 starsMedical Sector381st out of 939 stocksPharmaceutical Preparations Industry175th out of 435 stocks 4.5 Analyst's Opinion Consensus RatingJanux Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $59.60, Janux Therapeutics has a forecasted upside of 57.2% from its current price of $37.92.Amount of Analyst CoverageJanux Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted9.60% of the float of Janux Therapeutics has been sold short.Short Interest Ratio / Days to CoverJanux Therapeutics has a short interest ratio ("days to cover") of 4.6.Change versus previous monthShort interest in Janux Therapeutics has recently increased by 7.24%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldJanux Therapeutics does not currently pay a dividend.Dividend GrowthJanux Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for JANX. Previous Next 3.0 News and Social Media Coverage News SentimentJanux Therapeutics has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Janux Therapeutics this week, compared to 1 article on an average week.Search Interest46 people have searched for JANX on MarketBeat in the last 30 days. This is an increase of 557% compared to the previous 30 days.MarketBeat Follows13 people have added Janux Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Janux Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders35.40% of the stock of Janux Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions75.39% of the stock of Janux Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Janux Therapeutics are expected to decrease in the coming year, from ($1.40) to ($1.64) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Janux Therapeutics is -28.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Janux Therapeutics is -28.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioJanux Therapeutics has a P/B Ratio of 5.08. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaMajor Elon Musk Crypto Leak RevealedReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.Click here now to get your copy. About Janux Therapeutics Stock (NASDAQ:JANX)Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.Read More JANX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart JANX Stock News HeadlinesMarch 24, 2024 | americanbankingnews.comJanux Therapeutics, Inc. (NASDAQ:JANX) Receives $59.60 Average PT from BrokeragesMarch 22, 2024 | americanbankingnews.comJanux Therapeutics (NASDAQ:JANX) Shares Gap Up to $38.63March 28, 2024 | DTI (Ad)Warning: this could blow your mindBuckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…March 22, 2024 | americanbankingnews.comJanux Therapeutics (NASDAQ:JANX) Now Covered by BTIG ResearchMarch 21, 2024 | americanbankingnews.comJanux Therapeutics (NASDAQ:JANX) Coverage Initiated by Analysts at Cantor FitzgeraldMarch 20, 2024 | msn.comCantor starts Janux at overweight, cites TCE leadership positionMarch 20, 2024 | markets.businessinsider.comForecasting The Future: 4 Analyst Projections For Janux TherapeuticsMarch 20, 2024 | finance.yahoo.comCancer-Focused Janux Therapeutics Platform Has 'Tremendous Opportunity': AnalystMarch 28, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.March 20, 2024 | benzinga.comCancer-Focused Janux Therapeutics Platform Has 'Tremendous Opportunity': Analyst - Janux Therapeutics (NASDAQ:JANX)March 15, 2024 | investorplace.comJANX Stock Earnings: Janux Therapeutics Beats EPS, Beats Revenue for Q4 2023March 15, 2024 | fool.com2 Stocks That Have More Than Tripled This Year: Are They Buys?March 14, 2024 | markets.businessinsider.comStranahan Recommends Buy on Janux Therapeutics with Increased Price Objective Amid Promising Drug AdvancesMarch 13, 2024 | markets.businessinsider.comB of A Securities Maintains Buy Rating for Janux Therapeutics: Here's What You Need To KnowMarch 8, 2024 | msn.comJanux Therapeutics GAAP EPS of -$0.25 beats by $0.16, revenue of $2.46M beats by $1.72MMarch 8, 2024 | finance.yahoo.comJanux Therapeutics Inc (JANX) Reports Encouraging Clinical Data and Solid Financial Position ...March 8, 2024 | businesswire.comJanux Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business HighlightsMarch 2, 2024 | fool.comAfter Soaring 222% in 1 Day, Is Janux Therapeutics Stock a Buy?February 29, 2024 | msn.comJanux Therapeutics prices stock and warrants offering to raise $296.5MFebruary 29, 2024 | businesswire.comJanux Therapeutics Announces Pricing of $296.5 Million Underwritten Public Offering of Common Stock and Pre-Funded WarrantsFebruary 28, 2024 | seekingalpha.comJanux Therapeutics: Yes There's New Data; No It's Not A Buy HereFebruary 27, 2024 | msn.comJanux Therapeutics surges on upbeat trial data for prostate cancer therapyFebruary 27, 2024 | seekingalpha.comTrial Data Triggers Massive Rally In Janux TherapeuticsFebruary 27, 2024 | seekingalpha.comJanux: Additional Opportunity With JANX007 Dosing Update In The 2nd Half Of 2024February 27, 2024 | businesswire.comJanux Therapeutics Announces Proposed Public Offering of Common StockFebruary 27, 2024 | msn.comCancer-Focused Janux Therapeutics Stock Remains Undervalued Despite Price Surge After Study Data: AnalystFebruary 27, 2024 | finance.yahoo.comJanux Stock Launches 230% On Its 'Significant Opportunity' In Prostate Cancer TreatmentSee More Headlines Receive JANX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Janux Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2021Today3/28/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:JANX CUSIPN/A CIK1817713 Webwww.januxrx.com Phone858-751-4493FaxN/AEmployees64Year FoundedN/APrice Target and Rating Average Stock Price Target$59.60 High Stock Price Target$100.00 Low Stock Price Target$35.00 Potential Upside/Downside+57.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-58,290,000.00 Net Margins-721.18% Pretax Margin-721.18% Return on Equity-17.88% Return on Assets-15.95% Debt Debt-to-Equity RatioN/A Current Ratio26.80 Quick Ratio26.80 Sales & Book Value Annual Sales$8.08 million Price / Sales242.44 Cash FlowN/A Price / Cash FlowN/A Book Value$7.46 per share Price / Book5.08Miscellaneous Outstanding Shares51,660,000Free Float33,372,000Market Cap$1.96 billion OptionableOptionable Beta4.31 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesDr. David Alan Campbell Ph.D. (Age 64)President, CEO & Director Comp: $852.5kMr. Byron Robinson J.D. (Age 59)Ph.D., Chief Strategy Officer Comp: $606.8kMr. Tighe M. Reardon C.F.A. (Age 47)CPA, Acting Chief Financial Officer Mr. Charles M. Winter (Age 55)Chief Technical Officer Dr. Tommy Diraimondo Ph.D.Chief Scientific OfficerMr. James PenningtonGeneral CounselMs. Brenda Van VreeswykHead of Human ResourcesMr. Andy Hollman Meyer (Age 40)Chief Business Officer More ExecutivesKey CompetitorsNewAmsterdam PharmaNASDAQ:NAMSStructure TherapeuticsNASDAQ:GPCRAmphastar PharmaceuticalsNASDAQ:AMPHAvidity BiosciencesNASDAQ:RNAMaravai LifeSciencesNASDAQ:MRVIView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 37,202 shares on 3/11/2024Ownership: 2.121%Goldman Sachs Group Inc.Bought 25,404 shares on 3/1/2024Ownership: 0.087%Nuveen Asset Management LLCBought 14,872 shares on 2/15/2024Ownership: 0.177%Barclays PLCBought 29,800 shares on 2/15/2024Ownership: 0.103%Citadel Advisors LLCBought 300 shares on 2/15/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions JANX Stock Analysis - Frequently Asked Questions Should I buy or sell Janux Therapeutics stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Janux Therapeutics in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" JANX shares. View JANX analyst ratings or view top-rated stocks. What is Janux Therapeutics' stock price target for 2024? 6 brokers have issued 12-month price objectives for Janux Therapeutics' shares. Their JANX share price targets range from $35.00 to $100.00. On average, they anticipate the company's share price to reach $59.60 in the next year. This suggests a possible upside of 57.2% from the stock's current price. View analysts price targets for JANX or view top-rated stocks among Wall Street analysts. How have JANX shares performed in 2024? Janux Therapeutics' stock was trading at $10.73 at the beginning of the year. Since then, JANX shares have increased by 253.4% and is now trading at $37.92. View the best growth stocks for 2024 here. When is Janux Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our JANX earnings forecast. How were Janux Therapeutics' earnings last quarter? Janux Therapeutics, Inc. (NASDAQ:JANX) issued its quarterly earnings results on Tuesday, November, 9th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.18) by $0.08. The business had revenue of $1.16 million for the quarter. Janux Therapeutics had a negative net margin of 721.18% and a negative trailing twelve-month return on equity of 17.88%. What ETFs hold Janux Therapeutics' stock? ETFs with the largest weight of Janux Therapeutics (NASDAQ:JANX) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR) and Fidelity Disruptive Medicine ETF (FMED). When did Janux Therapeutics IPO? Janux Therapeutics (JANX) raised $152 million in an initial public offering (IPO) on Friday, June 11th 2021. The company issued 9,500,000 shares at a price of $15.00-$17.00 per share. BofA Securities, Cowen and Evercore ISI acted as the underwriters for the IPO and H.C. Wainwright & Co. LLC was co-manager. Who are Janux Therapeutics' major shareholders? Janux Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (2.12%), Vanguard Group Inc. (2.12%), Northern Trust Corp (0.44%), Nuveen Asset Management LLC (0.18%), Cerity Partners LLC (0.13%) and Janney Montgomery Scott LLC (0.11%). Insiders that own company stock include Corp Bregua, Orbimed Advisors Llc, Ra Capital Management, LP and Ventures Xi LP Avalon. View institutional ownership trends. How do I buy shares of Janux Therapeutics? Shares of JANX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:JANX) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBuy this small stock before coming AI Tidal WaveChaikin AnalyticsThe 3rd Revolution in WarfareWeiss RatingsDid You Get Your Free Bitcoin Yet?Crypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Janux Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.